About 7.5M results
Open links in new tab
Imfinzi Improves Survival Outcomes in Subgroups of Patients with …
Imfinzi is first and only immunotherapy to show survival benefit in ...
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in ... - AstraZeneca
Imfinzi Improves Survival in Small Cell Lung Cancer - NCI
IMFINZI® (durvalumab) is the first and only immunotherapy to …
FDA expands approval of Imfinzi to reduce the risk of non-small …
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 …
AstraZeneca immunotherapy extends survival by two years in rarer …
IMFINZI plus chemotherapy tripled patient survival at three years …
Imfinzi significantly improved overall survival and progression …
- Some results have been removed